drugset / Trial / NCT04430699
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
Phase 2
Active not recruiting
24 enrolled
Massachusetts General Hospital
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: * Cisplatin (standard of care drug) * Pembrolizumab (investigational drug) * Radiation Therapy (standard of care intervention)
Timeline
- Start
- 2020-07-29
- Primary completion
- 2026-04-30
- Completion
- 2028-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |